To view the Video Audio, please visit:
To view the release, please visit:
About Matinas BioPharma Holdings Inc
Matinas BioPharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal ("LNC") platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.
The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
In addition, the Company's proprietary, disruptive technology utilizes lipid nano-crystal cochleates to encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn and Facebook.
About The Ellis Martin Report
The Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.
Jenene Thomas Communications, LLC
T: (833) 475-8247
The Ellis Martin Report
VIDEO: Ellis Martin Report-Spotlight: Matinas Biopharma's (NYSE:MTNB) Jerome Jabbour on the Company's Prescription Omega-3
Ellis Martin Report with Neurotrope's (NASDAQ:NTRP) Dr. Daniel Alkon: Reversing Alzheimer's Disease.
Ellis Martin Report-SPOTLIGHT: EMX Royalty Corp (NYSE:EMX)-Royalty Cashflow De-Risking Exposure to Typical Development and Exploration Fallbacks for Mining Companies.
ELLIS MARTIN REPORT: ABEN RESOURCES (CVE:ABN) Begins Drilling in BC's Golden Triangle and Completes Drilling in the Canadian Yukon
VIDEO: Ellis Martin Report: Cypress Development Corp. (CVE:CYP) (OTCMKTS:CYDVF) Update on Prefeasibility Study for Company's Large Clayton Valley Lithium Project in Nevada
VIDEO: Ellis Martin Report: AMEX Exploration (CVE:AMX) (OTCMKTS:AMXEF) Super High Grade Gold in Quebec, Canada